SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN) announced today a collaboration with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform.

Myriad’s MyRisk ® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR ® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a ...

Recent Development at Myriad Genetics This month, Myriad Genetics partnered with Flatiron Health to integrate Myriad’s MyRisk ...

Myriad’s extensive proprietary database for MyRisk could enable the company to hold on to its market share and maintain durable price premiums. Myriad’s product portfolio faces limited ...

HighlightsThird quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

盐湖城 - 专门从事基因测试和精准医疗的Myriad Genetics, Inc. (NASDAQ: MYGN)宣布对联合健康最近的政策更新表示不同意。该保险公司计划从2025年1月1日起，在其商业和个人交换福利计划下限制多基因组药物基因组学测试的覆盖范围，包括Myriad的GeneSight测试。 这一政策变更于周五传达给Myriad，公司对此表示惊讶和失望。Myriad的总裁兼首席执行官Pau ...

This collaboration allows physicians to order Myriad’s MyRisk ® Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN) announced today a collaboration with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform. This ...

that allows physicians to order Myriad Genetics’ MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform ...